ガイドライン

(旧版) 肝癌診療ガイドライン2009年版

書誌情報
 
第4章 化学療法・放射線治療


表1 肝細胞癌化学療法投与法・薬剤別奏効率・生存期間(全身投与,単剤,30例以上)
表1 肝細胞癌化学療法投与法・薬剤別奏効率・生存期間(全身投与,単剤,30例以上)

■参考文献
1) LF03063 Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988;62(3):479-83.
2) LF03311 Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983;51(2):206-10.
3) LF03238 Colombo M, Tommasini MA, Del Ninno E, Rumi MG, De Fazio C, Dioguardi ML. Hepatocellular carcinoma in Italy:report of a clinical trial with intravenous doxorubicin. Liver 1985;5(6):336-41.
4) LF03265 Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK. Doxorubicin(75mg/m2)for hepatocellular carcinoma:clinical and pharmacokinetic results. Cancer Treat Rep 1984;68(3):487-91.
5) LF01957 Pohl J, Zuna I, Stremmel W, Rudi J. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001;47(5):359-65.
6) LF03107 Falkson G, Ryan LM, Johnson LA, Simson IW, Coetzer BJ, Carbone PP, et al. A random phaseII study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 1987;60(9):2141-5.
7) LF06222 Ravry MJ, Omura GA, Bartolucci AA, Einhorn L, Kramer B, Davila E. PhaseII evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma:a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986;70(2):311-2.
8) LF02416 Wall JG, Benedetti JK, O'Rourke MA, Natale RB, Macdonald JS. Phase II trial to topotecan in hepatocellular carcinoma:a Southwest Oncology Group study. Invest New Drugs 1997;15(3):257-60.
9) LF10201 Guan Z, Wang Y, Maoleekoonpairoj S, Chen Z, Kim WS, Ratanatharathorn V, et al. Prospective randomised phaseII study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 2003;89(10):1865-9.
10) LF12074 Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, et al. A phaseII trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002;94(12):3186-91.
11) LF10256 Hong RL, Tseng YL. A phaseII and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2003;51(5):433-8.
12) LF10198 Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, et al. A phaseII study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003;89(2):252-7.
13) LF10608 Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, et al. PhaseII trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs 2007;25(1):85-94.
14) LF10557 Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE. Long-acting octreotide versus placebo for treatment of advanced HCC:a randomized controlled double-blind study. Hepatology 2007;45(1):9-15.
15) LF11082 Treiber G, Rocken C, Wex T, Malfertheiner P. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer. Z Gastroenterol 2007;45(5):369-77.
16) LF12079 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors:randomized placebo-controlled trial. World J Gastroenterol 2007;13(23):3164-70.
17) LF01898 Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36(3):687-91.
18) LF10206 Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, et al. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 2006;95(7):853-61.


表2 肝細胞癌化学療法投与法・薬剤別奏効率・生存期間(全身投与,多剤,30例以上)
表2 肝細胞癌化学療法投与法・薬剤別奏効率・生存期間(全身投与,多剤,30例以上)

■参考文献
1) LF02402 Bobbio-Pallavicini E, Porta C, Moroni M, Bertulezzi G, Civelli L, Pugliese P, et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients:a phaseII study. Eur J Cancer 1997;33(11):1784-8.
2) LF10260 Kim SJ, Seo HY, Choi JG, Sul HR, Sung HJ, Park KH, et al. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2006;57(4):436-42.
3) LF10258 Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004;54(5):385-90.
4) LF07139 Yang TS, Wang CH, Hsieh RK, Chen JS, Fung MC. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma:a phaseI-II trial. Ann Oncol 2002;11(13):1771-8.
5) LF11014 Parikh PM, Fuloria J, Babu G, Doval DC, Awasthy BS, Pai VR, et al. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol 2005;26(3):115-8.
6) LF10247 Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, et al. Gemcitabine plus oxaliplatin(GEMOX)in patients with advanced hepatocellular carcinoma(HCC):results of a phase II study. Cancer 2007;109(7):1384-90.
7) LF12075 Li S, Niu Z, Tian H, Zhang B, Wang F, Yi LH, et al. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Hepatogastroenterology 2007;54(73):218-23.
8) LF10650 Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(12):1898-903.
9) LF10238 Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005;103(4):756-62.
10) LF12077 Yang TS, Chang HK, Chen JS, Lin YC, Liau CT, Chang WC. Chemotherapy using 5-fluorouracil,mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma:an analysis of 63 cases. J Gastroenterol 2004;39(4):362-9.
11) LF02516 Ji SK, Park NH, Choi HM, Kim YW, Lee SH, Lee KH, et al. Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma. Korean J Intern Med 1996;11(1):58-68.
12) LF10511 Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, et al. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. Hepatogastroenterology 2004;51(57):815-9.
13) LF10640 Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003;21(3):421-7.
14) LF10623 Feun LG, O'Brien C, Molina E, Rodriguez M, Jeffers L, Schiff ER, et al. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial. J Cancer Res Clin Oncol 2003;129(1):17-20.
15) LF10759 Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouraci(l PIAF)combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97(20):1532-8.
16) LF01883 Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin,interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94(2):421-7.


表3 肝細胞癌化学療法投与法・薬剤別奏効率・生存期間(肝動注,30例以上)
表3 肝細胞癌化学療法投与法・薬剤別奏効率・生存期間(肝動注,30例以上)

■参考文献
1) LF02215 Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 1999;46(26):1122-5.
2) LF01885 Court WS, Order SE, Siegel JA, Johnson E, DeNittis AS, Principato R, et al. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002;20(5-6):613-25.
3) LF00319 Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, et al. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999;6(3):587-91.
4) LF07140 Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis:analysis of 48 cases. Cancer 2002;3(95):588-95.
5) LF10033 Sumie S, Yamashita F, Ando E, Tanaka M, Yano Y, Fukumori K, et al. Interventional radiology for advanced hepatocellular carcinoma:comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol 2003;181(5):1327-34.
6) LF10151 Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003;23(2C):1891-7.
7) LF11663 Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007;110(1):129-37.
8) LF12076 Lin CP, Yu HC, Cheng JS, Lai KH, Lo GH, Hsu PI, et al. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma. J Chin Med Assoc 2004;67(12):602-10.
9) LF02089 Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88(9):1986-91.
10) LF01916 Kaneko S, Urabe T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 2002;62 Suppl 1:69-73.
11) LF10244 Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006;106(9):1990-7.


表4 肝細胞癌化学療法投与法・薬剤別奏効率・生存期間(経口投与,単剤,30例以上)
表4 肝細胞癌化学療法投与法・薬剤別奏効率・生存期間(経口投与,単剤,30例以上)

■参考文献
1) LF02005 Ishikawa T, Ichida T, Sugitani S, Tsuboi Y, Genda T, Sugahara S, et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stageIV -A hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16(4):452-9.
2) LF01965 Llovet JM, Ruff P, Tassopoulos N, Castells L, Bruix J, El-Hariry I, et al. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer 2001;37(11):1352-8.
3) LF12073 Benson AB 3rd, Mitchell E, Abramson N, Klencke B, Ritch P, Burnhan JP, et al. Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Ann Oncol 2002;13(4):576-81.
4) LF10230 Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.Cancer 2004;101(3):578-86.
5) LF02452 Suto T, Miyazawa J, Watanabe Y, Suto K, Yoshida Y, Sakata Y. The effect of YNK-01(an oral prodrug of cytarabine)on hepatocellular carcinoma. Semin Oncol 1997;24(2 Suppl 6):S6-122-S6-9.
6) LF10651 Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(26):4293-300.
7) LF10648 Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of Erlotinib(OSI-774)in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23(27):6657-63.
8) LF11026 Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, et al. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004;10(5):649-53.
9) LF10950 Hsu C, Chen CN, Chen LT, Wu CY, Hsieh FJ, Cheng AL. Effect of thalidomide in hepatocellular carcinoma:assessment with power doppler US and analysis of circulating angiogenic factors. Radiology 2005;235(2):509-16.
10) LF11682 Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003;65(3):242-9.

 

書誌情報